We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein replacement therapies for...
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase...
Evaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results. In September 2019...
BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study...
BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by...
BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data...
Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions